Miami, Florida, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR), through a licensing partnership with The Jenex Corporation (Jenex, NEX: JEN.H) will market, promote and distribute Jenex's new thermal therapy insect device under the trade name TherOZap™. TherOZap™ utilizes advanced thermal technology to provide relief from insect bites and stings. Rob Fia, Jenex CEO & Chairman comments: "TherOZap™ will offer consumers effective relief through an efficient and user-friendly experience." "We are very pleased with the pace of product development at Jenex and encouraged by the potential for TherOZap™." adds Luminar's CEO Chris Cook. "We are working closely with Jenex and expect to bring this novel solution to market in early 2017." About Jenex Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit: www.thejenexcorporation.com or www.interceptcs.com About Luminar: The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Luminar will bring this expertise to the TherOZap trade name. The company was started by entrepreneurs who can identify new tools to communicate with a target audience. At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm.